CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.488
EU - Europa 7.325
AS - Asia 6.774
SA - Sud America 1.074
Continente sconosciuto - Info sul continente non disponibili 287
AF - Africa 268
OC - Oceania 34
AN - Antartide 1
Totale 24.251
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.235
RU - Federazione Russa 3.427
SG - Singapore 2.488
CN - Cina 1.868
IT - Italia 950
GB - Regno Unito 805
BR - Brasile 800
VN - Vietnam 712
HK - Hong Kong 588
FR - Francia 440
DE - Germania 430
BD - Bangladesh 407
IE - Irlanda 364
SE - Svezia 271
FI - Finlandia 191
KR - Corea 191
UA - Ucraina 134
IN - India 121
CA - Canada 115
AR - Argentina 104
NL - Olanda 70
NG - Nigeria 62
ID - Indonesia 61
MX - Messico 60
EC - Ecuador 56
JP - Giappone 47
BJ - Benin 44
TR - Turchia 44
ZA - Sudafrica 44
AT - Austria 42
CO - Colombia 41
IQ - Iraq 41
PL - Polonia 41
ES - Italia 33
AU - Australia 31
PK - Pakistan 29
TN - Tunisia 25
SA - Arabia Saudita 24
CL - Cile 21
BE - Belgio 19
MA - Marocco 18
UZ - Uzbekistan 17
VE - Venezuela 17
PH - Filippine 16
GR - Grecia 15
LT - Lituania 15
MY - Malesia 15
PT - Portogallo 15
TG - Togo 15
KE - Kenya 14
CR - Costa Rica 13
EG - Egitto 13
PY - Paraguay 13
CH - Svizzera 11
NP - Nepal 11
PE - Perù 11
AE - Emirati Arabi Uniti 10
JM - Giamaica 10
TH - Thailandia 10
IL - Israele 9
NI - Nicaragua 9
TT - Trinidad e Tobago 8
DO - Repubblica Dominicana 7
EU - Europa 7
OM - Oman 7
AL - Albania 6
BO - Bolivia 6
HN - Honduras 6
KG - Kirghizistan 6
KZ - Kazakistan 6
RO - Romania 6
SV - El Salvador 6
TW - Taiwan 6
CZ - Repubblica Ceca 5
DK - Danimarca 5
ET - Etiopia 5
IR - Iran 5
JO - Giordania 5
PS - Palestinian Territory 5
QA - Qatar 5
AO - Angola 4
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
HU - Ungheria 4
PR - Porto Rico 4
RS - Serbia 4
SY - Repubblica araba siriana 4
BB - Barbados 3
CI - Costa d'Avorio 3
GT - Guatemala 3
HR - Croazia 3
KH - Cambogia 3
LB - Libano 3
PA - Panama 3
UY - Uruguay 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BY - Bielorussia 2
Totale 23.929
Salva come PNG Salva come JPEG
Città #
Singapore 1.298
Moscow 1.129
Ashburn 1.126
San Jose 1.064
Dallas 921
Southend 592
Hong Kong 580
Chandler 569
Jacksonville 564
Council Bluffs 386
Beijing 363
Dublin 356
Verona 327
The Dalles 311
Ho Chi Minh City 231
New York 219
Los Angeles 168
Munich 166
Hanoi 161
Princeton 153
Lawrence 152
Wilmington 150
Jinan 130
Woodbridge 113
Nanjing 111
Shenyang 110
Helsinki 109
Buffalo 94
Houston 92
São Paulo 84
Redondo Beach 83
Santa Clara 81
Tianjin 76
Milan 69
Hebei 68
London 57
Abuja 48
Zhengzhou 47
Orem 45
Cotonou 44
Sindelfingen 44
Tokyo 41
Changsha 40
Rome 40
Taizhou 40
Frankfurt am Main 39
Chicago 37
Guangzhou 37
Jiaxing 37
Columbus 36
Dearborn 36
Haikou 36
Phoenix 36
Ann Arbor 35
Bologna 35
Redmond 35
Jakarta 34
Toronto 34
Grafing 33
Seattle 33
Warsaw 33
Brooklyn 32
Hangzhou 32
Montreal 32
Dong Ket 31
Ningbo 31
Haiphong 30
Nanchang 29
San Francisco 27
Taiyuan 27
Chennai 26
Rio de Janeiro 26
Turku 26
Guayaquil 25
Lanzhou 24
Norwalk 24
Johannesburg 23
Denver 22
Belo Horizonte 21
Boston 21
Mexico City 21
Nuremberg 21
Amsterdam 20
Redwood City 20
Vienna 20
Atlanta 19
Baghdad 19
Dhaka 19
Fuzhou 19
Stockholm 19
Manchester 18
Washington 18
Da Nang 17
Mumbai 17
Salvador 17
Biên Hòa 16
Boardman 16
Lappeenranta 16
Melbourne 16
Naples 16
Totale 14.091
Salva come PNG Salva come JPEG
Nome #
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 306
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 288
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 233
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 226
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 221
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 218
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 203
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 194
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 190
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 182
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 182
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 182
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 180
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 177
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 175
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 174
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 173
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 172
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 170
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 168
A prognostic model for patients with lymphoma and {COVID}-19: a multicentre cohort study 168
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 166
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 166
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 166
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 164
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 162
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis 161
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 161
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 161
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 159
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 157
Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis 157
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 155
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report 154
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 154
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 153
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 152
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 151
Autoimmune cytopenias in chronic lymphocytic leukemia 151
Genetic and phenotypic attributes of splenic marginal zone lymphoma 151
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 149
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 149
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 147
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 147
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 146
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 145
Bendamustine plus rituximab: is it a BRIGHT idea? 143
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 142
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 141
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 141
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 140
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 140
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 139
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 138
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 137
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 135
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 135
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 135
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 134
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 130
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and {CAR}-T Cell Therapy 130
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 129
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 128
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 128
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 127
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 126
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma 125
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 125
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 125
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 124
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 124
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 123
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 122
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 122
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 122
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma 120
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 119
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 119
Aggressive B-cell Lymphoma with {MYC}/{TP}53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents 118
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 117
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 116
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 116
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 115
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 113
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 113
Different infiltration patterns within the tumor microenvironment can identify mantle cell lymphoma patients with different clinical outcomes. Results from a pilot clinical-pathological study 112
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 112
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 112
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium 112
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 112
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 112
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 112
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 112
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 110
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 109
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 109
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 109
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study 108
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 108
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network 106
Totale 14.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.719
article - articoli 81.906
book - libri 0
conference - conferenze 6.813
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.438
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022863 0 197 17 44 35 27 46 64 35 29 58 311
2022/20231.992 168 170 210 271 186 523 31 114 214 18 49 38
2023/20241.080 38 93 82 103 99 215 50 106 12 33 174 75
2024/20253.537 204 188 87 571 132 141 176 213 506 271 313 735
2025/202613.163 738 885 811 1.713 3.351 803 1.057 750 1.252 716 515 572
2026/2027800 366 434 0 0 0 0 0 0 0 0 0 0
Totale 24.251